What if a cancer patient could receive life-saving cellular therapy within days of diagnosis rather than weeks? What if pharmaceutical researchers could bring new treatments to market in months rather than years? Kytopen is significantly speeding up both discovery and delivery of engineered cell therapies with its transformative Flowfect platforms. The MIT spinout was co-founded by associate professor of mechanical engineering Cullen Buie and former MIT research scientist Paulo Garcia, now the company’s CEO. Cellular engineering is the process of enhancing or providing new capabilities to living cells, and producing…
